More specifically, asking participants and encouraging them to know and discuss their family history of prostate cancer, as well as other genetic conditions, should be required when applying SDM and developing interventions to address disparities in cancer prevention and early detection, particularly where guidelines recommend PSA screening for those with positive family histories. The gene discussed is KLK3; the disease is Familial prostate cancer.